The FDA’s review of drug and biological products in this medication class is critical, as a brain impairment impacts between 6.5% and 7.9% of adults in the United States.
Prescribing low-dose aspirin for preventing secondary cardiovascular disease is well established, but its safety and efficacy in primary prevention remains open to debate.
This drug class confers benefits in diabetic patients with heart failure, CV disease, and renal disease, but it is also associated with major adverse events.